As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market,

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated look at NVO stock prospects.

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.